FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285792204> ?p ?o ?g. }

• W4285792204 endingPage "90" @default.
• W4285792204 startingPage "71" @default.
• W4285792204 abstract "The eighth Paediatric Strategy Forum focused on multi-targeted kinase inhibitors (mTKIs) in osteosarcoma and Ewing sarcoma. The development of curative, innovative products in these tumours is a high priority and addresses unmet needs in children, adolescents and adults. Despite clinical and investigational use of mTKIs, efficacy in patients with bone tumours has not been definitively demonstrated.Randomised studies, currently being planned or in progress, in front-line and relapse settings will inform the further development of this class of product. It is crucial that these are rapidly initiated to generate robust data to support international collaborative efforts. The experience to date has generally indicated that the safety profile of mTKIs as monotherapy, and in combination with chemotherapy or other targeted therapy, is consistent with that of adults and that toxicity is manageable.Increasing understanding of relevant predictive biomarkers and tumour biology is absolutely critical to further develop this class of products. Biospecimen samples for correlative studies and biomarker development should be shared, and a joint academic-industry consortium created. This would result in an integrated collection of serial tumour tissues and a systematic retrospective and prospective analyses of these samples to ensure robust assessment of biologic effect of mTKIs.To support access for children to benefit from these novel therapies, clinical trials should be designed with sufficient scientific rationale to support regulatory and payer requirements. To achieve this, early dialogue between academia, industry, regulators, and patient advocates is essential. Evaluating feasibility of combination strategies and then undertaking a randomised trial in the same protocol accelerates drug development. Where possible, clinical trials and development should include children, adolescents, and adults less than 40 years.To respond to emerging science, in approximately 12 months, a multi-stakeholder group will meet and review available data to determine future directions and priorities." @default.
• W4285792204 created "2022-07-19" @default.
• W4285792204 creator A5000472375 @default.
• W4285792204 creator A5001066329 @default.
• W4285792204 creator A5003527979 @default.
• W4285792204 creator A5003957234 @default.
• W4285792204 creator A5006299598 @default.
• W4285792204 creator A5006570922 @default.
• W4285792204 creator A5007131512 @default.
• W4285792204 creator A5008077943 @default.
• W4285792204 creator A5011342082 @default.
• W4285792204 creator A5014514185 @default.
• W4285792204 creator A5018254405 @default.
• W4285792204 creator A5018886099 @default.
• W4285792204 creator A5019914745 @default.
• W4285792204 creator A5020485044 @default.
• W4285792204 creator A5024605312 @default.
• W4285792204 creator A5033219974 @default.
• W4285792204 creator A5039941717 @default.
• W4285792204 creator A5041362225 @default.
• W4285792204 creator A5045162042 @default.
• W4285792204 creator A5046880941 @default.
• W4285792204 creator A5046943976 @default.
• W4285792204 creator A5048397868 @default.
• W4285792204 creator A5049106961 @default.
• W4285792204 creator A5050571054 @default.
• W4285792204 creator A5050738935 @default.
• W4285792204 creator A5052706160 @default.
• W4285792204 creator A5055989413 @default.
• W4285792204 creator A5056053037 @default.
• W4285792204 creator A5061470535 @default.
• W4285792204 creator A5062088729 @default.
• W4285792204 creator A5062715691 @default.
• W4285792204 creator A5064402714 @default.
• W4285792204 creator A5065053322 @default.
• W4285792204 creator A5065105775 @default.
• W4285792204 creator A5066977204 @default.
• W4285792204 creator A5067202962 @default.
• W4285792204 creator A5071450479 @default.
• W4285792204 creator A5076197366 @default.
• W4285792204 creator A5079314843 @default.
• W4285792204 creator A5081920235 @default.
• W4285792204 creator A5083808934 @default.
• W4285792204 creator A5085820190 @default.
• W4285792204 creator A5086018137 @default.
• W4285792204 date "2022-09-01" @default.
• W4285792204 modified "2023-10-11" @default.
• W4285792204 title "Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas" @default.
• W4285792204 cites W1963882854 @default.
• W4285792204 cites W1988325237 @default.
• W4285792204 cites W2002586415 @default.
• W4285792204 cites W2007649418 @default.
• W4285792204 cites W2008922937 @default.
• W4285792204 cites W2014305454 @default.
• W4285792204 cites W2038586807 @default.
• W4285792204 cites W2044313879 @default.
• W4285792204 cites W2052299135 @default.
• W4285792204 cites W2072315137 @default.
• W4285792204 cites W2096387850 @default.
• W4285792204 cites W2097946365 @default.
• W4285792204 cites W2101776780 @default.
• W4285792204 cites W2105660237 @default.
• W4285792204 cites W2110022678 @default.
• W4285792204 cites W2115991409 @default.
• W4285792204 cites W2153080167 @default.
• W4285792204 cites W2155903913 @default.
• W4285792204 cites W2161680149 @default.
• W4285792204 cites W2164559547 @default.
• W4285792204 cites W2167348613 @default.
• W4285792204 cites W2169438753 @default.
• W4285792204 cites W2473766695 @default.
• W4285792204 cites W2536732763 @default.
• W4285792204 cites W2560083147 @default.
• W4285792204 cites W2591072493 @default.
• W4285792204 cites W2616094199 @default.
• W4285792204 cites W2742652175 @default.
• W4285792204 cites W2747333975 @default.
• W4285792204 cites W2756219586 @default.
• W4285792204 cites W2765831845 @default.
• W4285792204 cites W2769354967 @default.
• W4285792204 cites W2891557623 @default.
• W4285792204 cites W2892650455 @default.
• W4285792204 cites W2901259053 @default.
• W4285792204 cites W2904481169 @default.
• W4285792204 cites W2912132559 @default.
• W4285792204 cites W2913276036 @default.
• W4285792204 cites W2941090871 @default.
• W4285792204 cites W2954160784 @default.
• W4285792204 cites W2977223621 @default.
• W4285792204 cites W2983623050 @default.
• W4285792204 cites W3001622551 @default.
• W4285792204 cites W3006180429 @default.
• W4285792204 cites W3031790449 @default.
• W4285792204 cites W3032407418 @default.
• W4285792204 cites W3042051947 @default.
• W4285792204 cites W3042668923 @default.
• W4285792204 cites W3043105942 @default.
• W4285792204 cites W3082201370 @default.

• next